Navigation Links
Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer
Date:10/17/2007

GAITHERSBURG, Md., Oct. 17 /PRNewswire/ -- Panacea Pharmaceuticals, Inc. announced today that BC Detect(SM), the Company's serum-based breast cancer diagnostic test, is now available from Panacea Laboratories. BC Detect(SM) is a simple blood test that should facilitate the identification of recurrence among women successfully treated for breast cancer. Panacea Laboratories, a division of Panacea Pharmaceuticals, is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The blood sample can be ordered by any physician and sent to Panacea for testing; sample and shipping requirements are available at http://www.panacea-labs.com.

Breast cancer is the most common type of cancer in women accounting for 26% of female cancers. One in every eight women will develop breast cancer in their lifetime, placing the lifetime risk at 13%. More than 200,000 new cases of breast cancer will be diagnosed in the United States in 2007 and upwards of 2 million women are currently breast cancer survivors. Five-year survival rates for breast cancer are 98% for localized disease, 83% for regionally spread and 26% for distantly spread cancer. However, 25% of all metastases occur more than 5 years after the initial diagnosis and thus survival rates decrease as time goes out to 10 years due to disease recurrence. Methods to detect initial presentation of breast cancer as well as recurrence rely on imaging modalities, including mammography and MRI. No serum biomarkers have been approved for either primary breast cancer screening or monitoring for disease recurrence primarily due to relatively low specificities and sensitivities. In asymptomatic women in remission from breast cancer the guidelines of the major oncologic organizations only suggest annual mammography for detection of new tumors.

BC Detect(SM) measures levels of human aspartyl (asparaginyl) beta- hydroxylase (HAAH), a cancer molecular marker, in blood. HAAH has been detected by immunohistochemical staining (IHC) in a broad range of cancers including breast cancer. In addition, HAAH protein levels in serum have been demonstrated to be highly sensitive and specific for cancer in hundreds of patients with a range of cancer types, including breast cancer. Increased levels of HAAH have been found in the serum of 96% of women with breast cancer (n=157). In women not known to have cancer, HAAH was essentially undetectable in serum (n=32, specificity = 91%). HAAH was elevated in serum from women with all stages of breast cancer; mean serum HAAH levels for stages I - IV were 19, 13, 21 and 15 ng/ml, respectively. In addition, serum from women currently in remission (n=35) following treatment for breast cancer were also analyzed and found to be negative for HAAH.

"Measurement of serum HAAH levels using BC Detect(SM) has great promise as a diagnostic tool to monitor women with a history of breast cancer for disease recurrence", commented Pamela Jo Harris, MD, Vice President, Medical and Clinical Affairs at Panacea. "BC Detect(SM), in conjunction with routine follow-up imaging modalities should facilitate earlier identification of recurrent disease and prompt initiation of appropriate therapy."

About Panacea's Oncology Platform

In addition to BC Detect(SM), Panacea offers, PC Detect(SM), a diagnostic test used in conjunction with PSA and digital rectal exam to identify patients with prostate cancer, LC Detect(SM), a diagnostic test to aide in the detection of patients with lung cancer, and TK Sensesm, which determines whether white blood cells from patients with chronic myelogenous leukemia (CML) are sensitive or resistant to imatinib, the therapy of first choice for CML patients, prior to initiation of therapy.

The HAAH serum assay will be further developed as a diagnostic test for other types of cancer. Panacea is also pursuing the development of antibodies directed against HAAH as novel agents for the treatment of cancer with liver cancer as the first therapeutic indication. The Company is exploring both naked anti-HAAH antibodies as well as HAAH antibodies conjugated to chemotherapeutic agents and toxins. PAN-622 is an all-human sequence anti- HAAH monoclonal antibody that has demonstrated excellent efficacy in animals, and is currently in development as a cancer therapeutic.

About Panacea Pharmaceuticals, Inc.

Panacea Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on the development and commercialization of therapeutics and diagnostics for diseases with substantial, unmet clinical needs. The Company's product development strategy is based on novel therapeutic agents and approaches for cancer treatment, as well as acute and chronic neurodegenerative conditions, such as hypoxia-induced neurological insult, Parkinson's Disease, and Alzheimer's Disease. Panacea has an extensive patent portfolio covering its neurodegenerative and oncology technologies. Panacea Laboratories is a division of Panacea Pharmaceuticals, Inc.

More information about the Company is available at http://www.PanaceaPharma.com.

Except for historical information presented in this press release, matters discussed herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements are based on the opinions and estimates of management only as of the date of this release and are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance, or achievements expressed or implied by such statements. Factors that might cause such a difference include, but are not limited to, uncertainties related to our access to capital, the progress, costs, and results of any clinical trials undertaken by us, progress of our research and development projects, and uncertainties related to whether our product candidates would ultimately achieve commercial success. We do not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law.


'/>"/>
SOURCE Panacea Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   Acuant ... and verification solutions, has partnered with RightCrowd ... solutions for Visitor Management, Self-Service Kiosks and ... products that add functional enhancements to existing ... corporations and venues with an automated ID ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
Breaking Biology News(10 mins):